Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

Zepbound is an injectable medication approved by the U.S. Food and Drug Administration (FDA) for weight loss, and its key ingredient is tirzepatide. While Zepbound may be a powerful tool for ...

In the results, dual GLP-1/GIP agonist Zepbound (tirzepatide) outperformed GLP-1 agonist Wegovy (semaglutide) on all weight-loss endpoints at 72 weeks among patients with obesity or who were ...

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.

Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.